

# International Nonproprietary Names for Pharmaceutical Substances (INN)

---

## RECOMMENDED International Nonproprietary Names: List 54

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–91) and Recommended (1–52) International Nonproprietary Names can be found in *Cumulative List No. 11, 2004* (available in CD-ROM only).

## Dénominations communes internationales des Substances pharmaceutiques (DCI)

### Dénominations communes internationales RECOMMANDÉES: Liste 54

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–91) et recommandées (1–52) dans la *Liste récapitulative No. 11, 2004* (disponible sur CD-ROM seulement).

## Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

### Denominaciones Comunes Internacionales RECOMENDADAS: Lista 54

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Internacionales Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–91) y Recomendadas (1–52) se encuentran reunidas en *Cumulative List No. 11, 2004* (disponible sólo en CD-ROM).

**Latin**, English, French, Spanish:  
*Recommended INN*

*Chemical name or description; Molecular formula; Graphic formula*

*DCI Recommandée*

*Nom chimique ou description; Formule brute; Formule développée*

*DCI Recomendada*

*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

**acidum salclobuzicum**  
salclobuzic acid

4-(4-chloro-2-hydroxybenzamido)butanoic acid


acide salclobuzique

acide 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoïque

ácido salclobúxico

ácido 4-[(4-cloro-2-hidroxibenzoil)amino]butanoico

$C_{11}H_{12}ClNO_4$



**ancrivirocum**  
ancriviroc

3-({4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-4'-methyl-[1,4'-bipiperidin]-1'-yl}carbonyl)-2,4-dimethylpyridine-1-oxide


ancriviroc

4-[(Z)-(4-bromophényl)(éthoxyimino)méthyl]-1'-[(2,4-diméthyl-1-oxydopyridin-3-yl)carbonyl]-4'-méthyl-1,4'-bipéridinyle

ancriviroc

4-[(Z)-(4-bromofenil)(etoxiimino)metil]-1'-[(2,4-dimetil-1-oxidopiridin-3-il)carbonil]-4'-metil-1,4'-bipéridinilo

$C_{28}H_{37}BrN_4O_3$



**aplindorum**  
aplindore



(2S)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-8H-1,4-dioxino=[2,3-e]indol-8-one

aplindore

(2S)-2-[(benzylamino)méthyl]-2,3,7,9-tétrahydro-8H-1,4-dioxino=[2,3-e]indol-8-one

aplindor

(2S)-2-[(bencilamino)metil]-2,3,7,9-tetrahidro-8H-1,4-dioxino=[2,3-e]indol-8-ona



**atilmotinum**  
atilmotin



*N*-[(2*S*)-3-phenyl-2-(trimethylazaniumyl)propanoyl]-L-valyl-L-prolyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-tyrosylglycyl-L-glutamyl-L-leucyl-L-glutamyl-D-arginyl-L-leucyl-L-lysineamide

atilmotine

*N*-[(2*S*)-3-phényl-2-(triméthylammonio)propanoyle]-L-valyl-L-prolyl-L-isoleucyl-L-phénylalanyl-L-thréonyl-L-tyrosylglycyl-L-glutamyl-L-leucyl-L-glutamyl-D-arginyl-L-leucyl-L-lysineamide

atilmotina

*N*-[(2*S*)-3-fenil-2-(trimetilamonio)propanoil]-L-valil-L-prolil-L-isoleucil-L-fenilalanil-L-treonil-L-tirosilglicil-L-glutamil-L-leucil-L-glutaminiil-D-arginil-L-leucil-L-lisinamida



Leu—Gln—D-Arg—Leu—Lys—NH<sub>2</sub>

**avanafilum**  
avanafil



4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2*S*)-2-(hydroxymethyl)pyrrolidin-1-yl]-*N*-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide

avanafil

4-[(3-chloro-4-méthoxybenzyl)amino]-2-[(2*S*)-2-(hydroxyméthyl)=pyrrolidin-1-yl]-*N*-(pyrimidin-2-ylméthyl)pyrimidine-5-carboxamide

avanafilo

4-[(3-cloro-4-metoxibencil)amino]-2-[(2*S*)-2-(hidroximetil)pirrolidin-1-il]-*N*-(pirimidin-2-ilmetil)pirimidina-5-carboxamida



**balicatibum**


balicatib

*N*-{1-[(cyanomethyl)carbamoyl]cyclohexyl}-4-(4-propylpiperazin-1-yl)benzamide

balicatib

*N*-[1-[(cyanométhyl)carbamoyl]cyclohexyl]-4-(4-propylpipérazin-1-yl)benzamide

balicatib

*N*-[1-[(cianometil)carbamoi]ciclohexil]-4-(4-propilpiperazin-1-il)benzamida $C_{23}H_{33}N_5O_2$ **becatecarinum**


becatecarin

1,11-dichloro-6-[2-(diethylamino)ethyl]-12-(4-*O*-methyl- $\beta$ -D-glucopyranosyl)-12,13-dihydro-5*H*-indolo[2,3-*a*]pyrrolo=[3,4-*c*]carbazole-5,7(6*H*)-dione

bécatécarine

1,11-dichloro-6-[2-(diéthylamino)éthyl]-12-(4-*O*-méthyl- $\beta$ -D-glucopyranosyl)-12,13-dihydro-5*H*-indolo[2,3-*a*]pyrrolo=[3,4-*c*]carbazole-5,7(6*H*)-dione

becatecarina

1,11-dicloro-6-[2-(dietilamino)etil]-12-(4-*O*-metil- $\beta$ -D-glucopiranosil)-12,13-dihidro-5*H*-indolo[2,3-*a*]pirrolo[3,4-*c*]carbazol-5,7(6*H*)-diona $C_{33}H_{34}Cl_2N_4O_7$ 

**becocalcidiolum**


becocalcidiol

(1*R*,3*R*)-4-(2-[(1*R*,3*aS*,7*aR*)-1-[(2*S*)-butan-2-yl]-7*a*-methyloctahydro-4*H*-inden-4-ylidene)ethylidene)-2-methylenecyclohexane-1,3-diol

bécocalcidiol

(1*R*,3*R*)-2-méthylidène-5-[(2*E*)-2-[(1*R*,3*aS*,7*aR*)-7*a*-méthyl-1-[(1*S*)-1-méthylpropyl]octahydro-4*H*-indén-4-ylidène]éthylidène]=cyclohexane-1,3-diol

becocalcidiol

(1*R*,3*R*)-2-metilideno-5-[(2*E*)-2-[(1*R*,3*aS*,7*aR*)-7*a*-metil-1-[(1*S*)-1-metilpropil]octahidro-4*H*-inden-4-ilideno]etilideno]=ciclohexano-1,3-diolC<sub>23</sub>H<sub>36</sub>O<sub>2</sub>**bemotrizinolum**

bemotrizinol


2,2'-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl]bis={5-[(2-ethylhexyl)oxy]phenol}

bémotrizinol

2,2'-[6-(4-méthoxyphényl)-1,3,5-triazine-2,4-diyl]bis=[5-[(2-éthylhexyl)oxy]phénol]

bemotrizinol

2,2'-[6-(4-metoxifenil)-1,3,5-triazina-2,4-diil]bis[5-[(2-etilhexil)=oxi]fenol]

C<sub>38</sub>H<sub>49</sub>N<sub>3</sub>O<sub>5</sub>

**besilesomabum**

besilesomab

immunoglobulin G1, anti-(human CEA (carcinoembryonic antigen)-related antigen) (mouse monoclonal BW 250/183 heavy chain), disulfide with mouse monoclonal BW 250/183  $\kappa$ -chain, dimer

bésilésomab

immunoglobuline G1, anti-(molécules de l'adhésion cellulaire, antigènes carcinoembryonnaires humains (CEA ou CD66)), dimère du disulfure entre la chaîne lourde et la chaîne  $\kappa$  de l'anticorps monoclonal de souris BW 250/183

besilesomab

inmunoglobulina G1, anti-(moléculas de adhesión celular, antígenos carcinoembrionarios humanos (CEA o CD66)), dímero del disulfuro entre la cadena pesada y la cadena  $\kappa$  del anticuerpo monoclonal de ratón BW 250/183

**bisotrizolum**

bisotrizole


2,2'-methylenebis[6-(2*H*-benzotriazol-2-yl)-4-(2,4,4-trimethylpentan-2-yl)phenol]

bisotrizole

2,2'-méthylènebis[6-(2*H*-benzotriazol-2-yl)-4-(1,1,3,3-tétraméthylbutyl)phénol]

bisotrizol

2,2'-metilenobis[6-(2*H*-benzotriazol-2-il)-4-(1,1,3,3-tetrametilbutil)=fenol]

C<sub>41</sub>H<sub>50</sub>N<sub>6</sub>O<sub>2</sub>**canfosfamidum**

canfosfamide



*N*- $\gamma$ -L-glutaminy-3-(2-{bis[bis(2-chloroethyl)amino]=phosphoryl}ethanesulfonyl)-L-alanyl-(2*R*)-2-phenylglycine

canfosfamide

acide (2*S*)-2-amino-5-[[[(1*R*)-1-[[[2-{bis[bis(2-chloroéthyl)amino]=phosphinoyl]oxy]éthyl]sulfonyl]méthyl]-2-[[[(*R*)-carboxyphénylméthyl]=amino]-2-oxoéthyl]amino]-5-oxopentanoïque

canfosfamida

ácido (2*S*)-2-amino-5-[[[(1*R*)-1-[[[2-{bis[bis(2-cloroetil)amino]=fosfinoil]oxi]etil]sulfonil]metil]-2-[[[(*R*)-carboxifenilmetil]amino]-2-oxoetil]amino]-5-oxopentanoico



**ceftobiprolum**  
ceftobiprole


(6*R*,7*R*)-7-[(2*Z*)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)=acetamido]-8-oxo-3-[(*E*)-[(3'*R*)-2-oxo-1,3'-bipyrrolidin]-3-ylidene]=methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ceftobiprole

acide (6*R*,7*R*)-7-[(2*Z*)-(5-amino-1,2,4-thiadiazol-3-yl)=(hydroxyimino)acétyl]amino]-8-oxo-3-[(*E*)-[(3'*R*)-2-oxo-1,3'-bipyrrolidinyl]-3-ylidène]méthyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylique

ceftobiprol

ácido (6*R*,7*R*)-7-[(2*Z*)-(5-amino-1,2,4-tiadiazol-3-il)(hidroxiimino)=acetil]amino]-8-oxo-3-[(*E*)-[(3'*R*)-2-oxo-1,3'-bipirrolidinil-3-ilideno]metil]-5-tia-1-azabíciclo[4.2.0]oct-2-eno-2-carboxílico



**ceftobiprolum medocarilum**  
ceftobiprole medocaril



(6*R*,7*R*)-7-[(2*Z*)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)=acetamido]-3-[(*E*)-[(3'*R*)-1'-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxycarbonyl]-2-oxo-1,3'-bipyrrolidin]-3-ylidene)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ceftobiprole médocaril

acide (6*R*,7*R*)-7-[(2*Z*)-(5-amino-1,2,4-thiadiazol-3-yl)=(hydroxyimino)acétyl]amino]-3-[(*E*)-[(3'*R*)-1'-[(5-méthyl-2-oxo-1,3-dioxol-4-yl)méthoxy]carbonil]-2-oxo-1,3'-bipyrrolidinyl-3-ylidène]méthyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylique

ceftobiprol medocarilo

ácido (6*R*,7*R*)-7-[(2*Z*)-(5-amino-1,2,4-tiadiazol-3-il)(hidroxiimino)=acetamido]-3-[(*E*)-[(3'*R*)-1'-[(5-metil-2-oxo-1,3-dioxol-4-il)metoxi]carbonil]-2-oxo-1,3'-bipirrolidinil-3-ilideno]metil]-8-oxo-5-tia-1-azabíciclo[4.2.0]oct-2-eno-2-carboxílico

**cintredekinum besudotoxum**

cintredekin besudotox


cintredékine bésudotox

toxin hIL13-PE38QQR (plasmid phuIL13-Tx)

[Met<sup>17</sup>, His<sup>18</sup>]précurseur de l'interleukine-13 humaine-(17-132)-peptide (132→246)-protéine avec la  
 dès-Ala<sup>365</sup>, Asp<sup>366</sup>, Val<sup>367</sup>, Val<sup>368</sup>, Ser<sup>369</sup>, Leu<sup>370</sup>, Thr<sup>371</sup>, Cys<sup>372</sup>, Pro<sup>373</sup>, Val<sup>374</sup>,  
 Ala<sup>375</sup>, Ala<sup>376</sup>, Gly<sup>377</sup>, Glu<sup>378</sup>, Cys<sup>379</sup>, Ala<sup>380</sup>-  
 [Lys<sup>246</sup>, Ala<sup>247</sup>, Ser<sup>248</sup>, Gly<sup>249</sup>, Gly<sup>250</sup>, Asn<sup>364</sup>, Val<sup>407</sup>, Ser<sup>515</sup>, Gln<sup>590</sup>,  
 Gln<sup>606</sup>, Arg<sup>613</sup>]exotoxine A (*Pseudomonas aeruginosa*)-(246-613)-  
 peptide

cintredekina besudotox

toxina hIL13-PE38QQR (plásmido phuIL13-Tx)



|            |            |            |            |
|------------|------------|------------|------------|
| MHSPGPVPPS | TALRELIEEL | VNITQNQKAP | LCNGSMVWSI |
| NLTAGMYCAA | LESLINVSGC | SAIEKTQRM  | SGFCPHKVSA |
| GQFSSLHVRD | TKIEVAQFVK | DLLLHLKKLF | REGFRNKASG |
| GPEGGLAAL  | TAHQACHLPL | ETFTRHRQPR | GWEQLEQCGY |
| PVQRLVALYL | AARLSWNQVD | QVIRNALASP | GSGGDLGEAI |
| REQPEQARLA | LTAAAESER  | FVRQGTGNDE | AGAANGPADS |
| GDALLERNYP | TGAEFLGDGG | DVSFSTRGTQ | NWTVERLLQA |
| HRQLEERGYV | FVGYHGTGLE | AAQSIVFGGV | RARSQDLDAI |
| WRGYIAGDP  | ALAYGYAQDQ | EPDARGRIRN | GALLRVYVPR |
| SSLPGFYRTS | LTAAPEAAG  | EVERLIGHPL | PLRLDAITGP |
| EEEGGRLETI | LGWPLAERTV | VIPSAIPTDP | RNVGGDLDP  |
| SIPDQEQAIS | ALPDYASQPG | QPPREDLR   |            |

**davaisaicinum**

davaisaicin



2-[4-(2-aminoethoxy)-3-methoxyphenyl]-N-[3-(3,4-dimethylphenyl)=propyl]acetamide

davaisaïcine

2-[4-(2-aminoéthoxy)-3-méthoxyphényl]-N-[3-(3,4-diméthylphényl)=propyl]acétamide

davaisaicina

2-[4-(2-aminoetoxi)-3-metoxifenil]-N-[3-(3,4-dimetilfenil)propil]=acetamida





**deferitrium**


deferitrim

(4*S*)-2-(2,4-dihydroxyphenyl)-4-methyl-4,5-dihydro-1,3-thiazole-4-carboxylic acid

déféritrine

acide (+)-(4*S*)-2-(2,4-dihydroxyphényl)-4-méthyl-4,5-dihydrothiazole-4-carboxylique

deferitrima

ácido (+)-(4*S*)-2-(2,4-dihidroxifenil)-4-metil-4,5-dihidrotiazol-4-carboxílicoC<sub>11</sub>H<sub>11</sub>NO<sub>4</sub>S**delmitidum**


delmitide

(2*R*)-2-[(2*R*)-2-[(2*R*)-2-[(2*R*)-2-[(2*R*)-2-(D-arginylamino)=hexanamido]hexanamido]hexanoyl-D-arginylamino]=hexanamido]hexanamido]hexanoylglycyl-D-tyrosinamide

delmitide

D-arginyl-(2*R*)-2-aminohexanoyl-(2*R*)-2-aminohexanoyl-(2*R*)-2-aminohexanoyl-D-arginyl-(2*R*)-2-aminohexanoyl-(2*R*)-2-aminohexanoylglycyl-D-tyrosinamide

delmitida

D-arginil-(2*R*)-2-aminohexanoil-(2*R*)-2-aminohexanoil-(2*R*)-2-aminohexanoil-D-arginil-(2*R*)-2-aminohexanoil-(2*R*)-2-aminohexanoilglycil-D-tirosinamidaC<sub>59</sub>H<sub>105</sub>N<sub>17</sub>O<sub>11</sub>**deutolperisonum**

deutolperisone



2-methyl-1-(4-([<sup>2</sup>H<sub>3</sub>]methyl)[2,3,5,6-<sup>2</sup>H<sub>4</sub>]phenyl)-3-(piperidin-1-yl)propan-1-one

deutolpérisone

(2*RS*)-2-méthyl-1-(4-(<sup>2</sup>H<sub>3</sub>)méthyl(2,3,5,6-<sup>2</sup>H<sub>4</sub>)phényl)-3-(pipéridin-1-yl)propan-1-one

deutolperisona

(2*RS*)-2-metil-1-(4-[<sup>2</sup>H<sub>3</sub>]metil[2,3,5,6-<sup>2</sup>H<sub>4</sub>]fenil)-3-(piperidin-1-il)propan-1-ona

**efipladibum**

efipladib



4-(3-[5-chloro-2-[2-[[[(3,4-dichlorophenyl)methyl]sulfonyl]amino]ethyl]-1-(diphenylmethyl)-1*H*-indol-3-yl]propyl)benzoic acid

éfipladib

acide 4-[3-[5-chloro-2-[2-[[[(3,4-dichlorobenzyl)sulfonyl]amino]éthyl]-1-(diphénylméthyl)-1*H*-indol-3-yl]propyl]benzoïque

efipladib

ácido 4-[3-[5-cloro-2-[2-[[[(3,4-diclorobencil)sulfonil]amino]etil]-1-(difenilmetil)-1*H*-indol-3-il]propil]benzoico

**elomotecanum**

elomotecan



(5*R*)-9-chloro-5-ethyl-5-hydroxy-10-methyl-12-[(4-methylpiperidin-1-yl)methyl]-1,4,5,13-tetrahydro-3*H*,15*H*-oxepino[3',4':6,7]=indolizino[1,2-*b*]quinoline-3,15-dione

élototécan

(5*R*)-9-chloro-5-éthyl-5-hydroxy-10-méthyl-12-[(4-méthylpipéridin-1-yl)méthyl]-1,4,5,13-tétrahydro-3*H*,15*H*-oxépino[3',4':6,7]=indolizino[1,2-*b*]quinoléine-3,15-dione

elomotecán

(5*R*)-9-cloro-5-etil-5-hidroxi-10-metil-12-[(4-metilpiperidin-1-il)metil]-1,4,5,13-tetrahidro-3*H*,15*H*-oxepino[3',4':6,7]indolizino=[1,2-*b*]quinolina-3,15-diona



**embeconazolum**

embeconazole


4-[(1*E*,3*E*)-4-(*trans*-5-[[[(2*R*,3*R*)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1*H*-1,2,4-triazol-1-yl)butan-2-yl]sulfanyl]-1,3-dioxan-2-yl)buta-1,3-dien-1-yl]-3-fluorobenzonitrile

embéconazole

(-)-4-[(1*E*,3*E*)-4-[*trans*-5-[[[(1*R*,2*R*)-2-(2,4-difluorophényl)-2-hydroxy-1-méthyl-3-(1*H*-1,2,4-triazol-1-yl)propyl]sulfanyl]-1,3-dioxan-2-yl]buta-1,3-diényl]-3-fluorobenzonitrile

embeconazol

(-)-4-[(1*E*,3*E*)-4-[*trans*-5-[[[(1*R*,2*R*)-2-(2,4-difluorofenil)-2-hidroxi-1-metil-3-(1*H*-1,2,4-triazol-1-il)propil]sulfanil]-1,3-dioxan-2-il]buta-1,3-dienil]-3-fluorobenzonitrilo

C<sub>27</sub>H<sub>25</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S**epoetinum zeta**

epoetin zeta

1-165-erythropoietin (human clone B03XA01), glycoform ζ

époétine zêta

1-165-érythropoïétine (humaine B03XA01), glycoforme ζ

epoetina zeta

1-165-eritropoyetina (humana B03XA01), glicoforma ζ

C<sub>809</sub>H<sub>1301</sub>N<sub>229</sub>O<sub>240</sub>S<sub>5</sub>**eritoranum**

eritoran



2-deoxy-3- O-[(3*R*)-3-methoxydecyl]-6- O-methyl-2-(octadec-11-enamido)-4- O-phosphono-β-D-glucopyranosyl-(1→6)-3- O-decyl-2-deoxy-2-(3-oxotetradecanamido)-α-D-glucopyranose 1-(dihydrogen phosphate)

éritoran

dihydrogénophosphate de 3- O-décyl-2-désoxy-6- O-[2-désoxy-3- O-[(3*R*)-3-méthoxydécyl]-6- O-méthyl-2-[(11*Z*)-octadéc-11-énoylamino]-4- O-phosphono-β-D-glucopyranosyl]-2-[(3-oxotétradécanoyl)amino]-α-D-glucopyranosyle

eritorán

dihidrógenofosfato de 3- O-decil-2-desoxi-6- O-[2-desoxi-3- O-[(3*R*)-3-metoxidécil]-6- O-metil-2-[(11*Z*)-octadec-11-enamido]-4- O-fosfono-β-D-glucopiranosil]-2-(3-oxotetradecanamido)-α-D-glucopiranosilo

**etalocibum**

etalocib



2-{3-[3-[(5-ethyl-4'-fluoro-2-hydroxy-[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy}benzoic acid

étalocib

acide 2-[3-[3-[(5-éthyl-4'-fluoro-2-hydroxybiphényl-4-yl)oxy]propoxy]-2-propylphénoxy]benzoïque

etalocib

ácido 2-[3-[3-[(5-etil-4'-fluoro-2-hidroxibifenil-4-il)oxi]propoxi]-2-propilfenoxi]benzoico

**farampatorum**

farampator



5-[(piperidin-1-yl)carbonyl]-2,1,3-benzoxadiazole

farampator

1-(2,1,3-benzoxadiazol-5-ylcarbonyl)pipéridine

farampator

1-(2,1,3-benzoxadiazol-5-ilcarbonyl)piperidina

**forodesinum**

forodesine



7-(5-amino-1,5-dideoxy-β-D-ribofuranos-1-yl)-1,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one

forodésine

(-)-7-[(2*S*,3*S*,4*R*,5*R*)-3,4-dihydroxy-5-(hydroxyméthyl)pyrrolidin-2-yl]-1,5-dihydro-4*H*-pyrrolo[3,2-*d*]pyrimidin-4-one


forodesina

(-)-7-[(2*S*,3*S*,4*R*,5*R*)-3,4-dihidroxi-5-(hidroximetil)pirrolidin-2-il]-1,5-dihidro-4*H*-pirrolo[3,2-*d*]pirimidin-4-ona



**galsulfasum**  
galsulfase  
  
galsulfase  
  
galsulfasa

*N*-acetylgalactosamine 4-sulfatase (human CSL4S-342 cell)  
*N*-acétylgalactosamine 4-sulfatase (cellule humaine CSL4S-342)  
*N*-acetilgalactosamina 4-sulfatasa (célula humana CSL4S-342)



|            |             |            |            |
|------------|-------------|------------|------------|
| AGASRPPHLV | FLLADDLGWN  | DVGFGSRIR  | TPHLDALAAG |
| GVLLDNYYTQ | PLCTPSRSQL  | LTGRYQIRTG | LQHQIIWPCQ |
| PSCVPLDEKL | LPQLLKEAGY  | TTHMVGKWL  | GMYRKECLPT |
| RRGFDTYFGY | LLGSEDYYSH  | ERCTLIDALN | VTRCALDFRD |
| GEEVATGYKN | MYSTNIFTKR  | AIALITNHPP | EKPLFLYLAL |
| QSVHEPLQVP | EEYLKPYDFI  | QDKNRHHYAG | MVSLMDEAVG |
| NVTAAKSSG  | LWNNTVFIFS  | TDNGGQTLAG | GNNWPLRGRK |
| WSLWEGGVRG | VGFBVASPLLK | QKGVKNRELI | HISDWLPTLV |
| KLARGHTNGT | KPLDGFVWK   | TISEGSPSPR | IELLNIDPN  |
| FVDSSPCPRN | SMAPAKDDSS  | LPEYSAFNST | VHAAIRHGNW |
| KLGTGYPCG  | YWFPPPSQYN  | VSEIPSSDPP | TKTLWLFDID |
| RDPEERHDL  | REYPHIVTKL  | LSRLQFYHKK | SVPVYFPAQD |
| PRCDPKATGV | WGPWM       |            |            |

**glucarpidasum**  
glucarpidase  
  
glucarpidase  
  
glucarpidasa

recombinant glutamate carboxypeptidase (carboxypeptidase G2)  
[405-arginine]précurseur de la carboxypeptidase G2 de *Pseudomonas* (RS-16), enzyme à zinc dimérique, glutamate carboxypeptidase  
glutamato carboxipeptidasa recombinante (carboxipeptidasa G2)

**C<sub>1950</sub>H<sub>3157</sub>N<sub>543</sub>O<sub>599</sub>S<sub>7</sub> (monomer)**

|            |            |            |             |
|------------|------------|------------|-------------|
| MRPSIHRTAI | AAVLATAFVA | GTALAQKRDN | VLFQAATDEQ  |
| PAVIKTLEKL | VNIETGTGDA | EGIAAAGNFL | EAEKLNLF    |
| VTRSKSAGLV | VGDNIVGKIK | GRGGKNLLLM | SHMDTVYLLG  |
| ILAKAPFRVE | GDKAYGPGIA | DDKGGNAVIL | HTLKLKEYG   |
| VRDYGTITVL | FNTDEEKGSF | GSRDLIQEEA | KLADYVLSFE  |
| PTSAGDEKLS | LGTSGIAYVQ | VNITGKASHA | GAAPELGVNA  |
| LVEASDLVLR | TMNIDDKAKN | LRFNWTIACA | GNVSNIIIPAS |
| ATLNADVRYA | RNEFDFAAMK | TLEERAQQKK | LPEADVQVIV  |
| TRGRPAFNAG | EGGKKLVDKA | VAYYKEAGGT | LGVEERTGGG  |
| TDAAYAALSG | KPVIESLGLP | GFGYHSDKAE | YVDISAIPRR  |
| LYMARRLIMD | LGAGK      |            |             |

**iboctadekinum**

iboctadekin

a recombinant human interleukin-18 with 157 amino acids

iboctadékin

interleukine-18 humaine recombinante (157 aminoacides)

iboctadekina

interleukina-18 humana recombinante (157 aminoácidos)

**C<sub>801</sub>H<sub>1264</sub>N<sub>212</sub>O<sub>252</sub>S<sub>10</sub>**

|            |            |            |            |
|------------|------------|------------|------------|
| YFGKLESKLS | VIRNLNDQVL | FIDQGNRPLF | EDMTDSDCRD |
| NAPRTIFIIS | MYKDSQPRGM | AVTISVKCEK | ISTLSCENKI |
| ISFKEMNPPD | NIKDTKSDII | FFQRSVPGHD | NKMQFESSY  |
| EGYFLACEKE | RDLFKLILKK | EDELGDRSIM | FTVQNED    |

**icomucretum**

icomucret


(5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoic acid

icomucret

acide (5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tétraénoïque

icomucret

ácido (5Z,8Z,11Z,13E,15S)-15-hidroxiicosa-5,8,11,13-tetraenoico

**C<sub>20</sub>H<sub>32</sub>O<sub>3</sub>**

**inotuzumabum ozogamicinum**

inotuzumab ozogamicin


immunoglobulin G4, anti-(human CD22 (antigen)) (human-mouse monoclonal G544 heavy chain), disulfide with human-mouse monoclonal G544  $\kappa$ -chain, dimer, conjugate with methyl *N*-((1*R*,4*Z*,8*S*,13*E*)-8-(4,6-dideoxy-4-((4-*S*-{4-[(6-deoxy-3-*O*-methyl- $\alpha$ -L-mannopyranosyl)oxy]-3-iodo-5,6-dimethoxy-2-methylbenzoyl)-4-thio- $\beta$ -D-ribo-hexopyranosyl)oxy)amino)-2-*O*-[4-(*N*-ethylacetamido)-2,4-dideoxy-3-*O*-methyl- $\alpha$ -L-threo-pentopyranosyl]- $\beta$ -D-glucopyranosyloxy)-13-[2-({4-[2-(1-{4-(4-amino-4-oxobutyl)oxy}phenyl)ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl}disulfany)ethylidene]-1-hydroxy-11-oxobicyclo[7.3.1]trideca-4,9-diene-2,6-diyn-10-yl)carbamate

inotuzumab ozogamicine

*N*-[4-[4-[1-[3-[[2-[(1*R*,4*Z*,8*S*,13*E*)-8-[[2-*O*-[4-(acétyléthylamino)-2,4-didésoxy-3-*O*-méthyl- $\alpha$ -L-*thréo*-pentopyranosyl]-4,6-didésoxy-4-[[[2,6-didésoxy-4-*S*-[4-[(6-désoxy-3-*O*-méthyl- $\alpha$ -L-mannopyranosyl)oxy]-3-iodo-5,6-diméthoxy-2-méthylbenzoyl]-4-thio- $\beta$ -D-ribo-hexopyranosyl]oxy]amino]- $\beta$ -D-glucopyranosyl]oxy]-1-hydroxy-10-[(méthoxycarbonyl)amino]-11-oxobicyclo[7.3.1]tridéca-4,9-diène-2,6-diyn-13-ylidène]éthyl]disulfany]-3-méthylbutanoyl]=diazanylidène]éthyl]phénoxy]butanoyl]immunoglobuline G4, anti-(antigène CD22 humain) dimère du disulfure entre la chaîne lourde et la chaîne  $\kappa$  de l'anticorps monoclonal de souris G544 humanisé

inotuzumab ozogamicina

*N*-[4-[4-[1-[3-[[2-[(1*R*,4*Z*,8*S*,13*E*)-8-[[2-*O*-[4-(acetiletilamino)-2,4-didesoxi-3-*O*-metil- $\alpha$ -L-treo-pentopiranosil]-4,6-didesoxi-4-[[[2,6-didesoxi-4-*S*-[4-[(6-desoxi-3-*O*-metil- $\alpha$ -L-manopiranosil]oxi]-3-iodo-5,6-dimetoxi-2-metilbenzoil]-4-tio- $\beta$ -D-ribo-hexopiranosil]=oxi]amino]- $\beta$ -D-glucopiranosil]oxi]-1-hidroxi-10-[(metoxicarbonil)=amino]-11-oxobiciclo[7.3.1]trideca-4,9-dieno-2,6-diino-13-ilideno]etil]disulfanil]-3-metilbutanoil]diazanilideno]etil]fenoxi]=butanoil]inmunoglobulina G4, anti-(antígeno CD22 humano) dimero del disulfuro entre la cadena pesada y la cadena  $\kappa$  del anticuerpo monoclonal humanizado de ratón G544

C<sub>6518</sub>H<sub>10002</sub>N<sub>1738</sub>O<sub>2036</sub>S<sub>42</sub>Ig-NH<sub>2</sub> = inotuzumab

**isalmadolum**


isalmadol

3-[(1*RS*,2*RS*)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenyl  
2-hydroxybenzoate

isalmadol

2-hydroxybenzoate de 3-[(1*RS*,2*RS*)-2-[(diméthylamino)méthyl]-  
1-hydroxycyclohexyl]phényle

isalmadol

2-hidroxibenzoato de 3-[(1*RS*,2*RS*)-2-[(dimetilamino)metil]-  
1-hidroxiciclohexil]fenilo $C_{22}H_{27}NO_4$ **ispinesibum**


ispinesib

*N*-(3-aminopropyl)-*N*-[(1*R*)-1-(3-benzyl-7-chloro-4-oxo-  
3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide

ispínésib

*N*-(3-aminopropil)-*N*-[(1*R*)-1-(3-benzil-7-cloro-4-oxo-  
3,4-dihidroquinazolin-2-il)-2-méthylpropil]-4-méthylbenzamide

ispinesib

*N*-(3-aminopropil)-*N*-[(1*R*)-1-(3-bencil-7-cloro-4-oxo-  
3,4-dihidroquinazolin-2-il)-2-metilpropil]-4-metilbenzamida $C_{30}H_{33}ClN_4O_2$ **levotofisopamum**

levotofisopam

(5*S*)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-  
5*H*-2,3-benzodiazepine



lévotofisopam

(-)-(5*S*)-1-(3,4-diméthoxyphényl)-5-éthyl-7,8-diméthoxy-4-méthyl-  
5*H*-2,3-benzodiazépine

levotofisopam

(-)-(5*S*)-1-(3,4-dimetoxifenil)-5-etil-7,8-dimetoxi-4-metil-  
5*H*-2,3-benzodiazepina



**linaprazanum**



linaprazan

8-[(2,6-diméthylphenyl)méthyl]amino]-*N*-(2-hydroxyéthyl)-2,3-diméthylimidazo[1,2-*a*]pyridine-6-carboxamide

linaprazan

8-[(2,6-diméthylbenzyl)amino]-*N*-(2-hydroxyéthyl)-2,3-diméthylimidazo[1,2-*a*]pyridine-6-carboxamide

linaprazán

8-[(2,6-diméthylbenzyl)amino]-*N*-(2-hidroxiéthyl)-2,3-diméthylimidazo[1,2-*a*]piridina-6-carboxamida**morphini glucuronidum**



morphine glucuronide

3-hydroxy-17-méthyl-4,5 $\alpha$ -époxy-morphin-7-en-6 $\alpha$ -yl  $\beta$ -D-glucopyranosiduronic acid

glucuronide de morphine

acide  $\beta$ -D-glucopyranosidurique de 7,8-didéshydro-4,5 $\alpha$ -époxy-3-hydroxy-17-méthylmorphinan-6 $\alpha$ -yle

glucurónido de morfina

ácido  $\beta$ -D-glucopiranosidurónico de 7,8-dideshidro-4,5 $\alpha$ -epoxi-3-hidroxi-17-metilmorfinan-6 $\alpha$ -ilo

**naveglitazarum**


naveglitazar

(2*S*)-2-methoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl]=propanoic acid

navéglitazar

acide (2*S*)-2-méthoxy-3-[4-[3-(4-phénoxyphénoxy)propoxy]phényl]=propanoïque

naveglitazar

ácido (2*S*)-2-metoxi-3-[4-[3-(4-fenoxifenoxi)propoxi]fenil]propanoicoC<sub>25</sub>H<sub>26</sub>O<sub>6</sub>**omocianinum**


omocianine

2-[(1*E*,3*E*,5*E*)-7-[(2*E*)-3,3-dimethyl-5-sulfonato-1-(2-sulfonatoethyl)-1,3-dihydro-2*H*-indol-2-ylidene]-4-methylhepta-1,3,5-trienyl]-3,3-dimethyl-1-(2-sulfonatoethyl)-3*H*-indolium-5-sulfonate

omocianine

trihidrogéno-2-[(1*E*,3*E*,5*E*)-7-[(2*E*)-3,3-diméthyl-5-sulfonato-1-(2-sulfonatoéthyl)-1,3-dihydro-2*H*-indol-2-ylidène]-4-méthylhepta-1,3,5-triényl]-3,3-diméthyl-1-(2-sulfonatoéthyl)-3*H*-indolium-5-sulfonate

omocianina

trihidrógeno-2-[(1*E*,3*E*,5*E*)-7-[(2*E*)-3,3-dimetil-5-sulfonato-1-(2-sulfonatoetil)-1,3-dihidro-2*H*-indol-2-ilideno]-4-metilhepta-1,3,5-trienil]-3,3-dimetil-1-(2-sulfonatoetil)-3*H*-indolio-5-sulfonatoC<sub>32</sub>H<sub>38</sub>N<sub>2</sub>O<sub>12</sub>S<sub>4</sub>**peliglitazarum**


peliglitazar

*N*-[(4-methoxyphenoxy)carbonyl]-*N*-[(1*S*)-1-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]ethyl]glycine

péliglitazar

acide [[(4-méthoxyphénoxy)carbonyl]][(1*S*)-1-[4-[2-(5-méthyl-2-phényloxazol-4-yl)éthoxy]phényl]éthyl]amino]acétique

peliglitazar

ácido [[[4-metoxifenoxi]carbonil]][(1*S*)-1-[4-[2-(5-metil-2-feniloxazol-4-il)etoxi]fenil]etil]amino]acéticoC<sub>30</sub>H<sub>30</sub>N<sub>2</sub>O<sub>7</sub>

**pemaglitazarum**


pemaglitazar

(2S)-4-[(2-methylphenyl)sulfanyl]-2-[4-(trifluoromethyl)phenoxy]=  
butanoic acid

pémaglitazar

(-)-acide (2S)-4-[(2-méthylphényl)sulfanyl]-2-[4-(trifluorométhyl)=  
phénoxy]butanoïque

pemaglitazar

(-)-ácido (2S)-4-[(2-metilfenil)sulfanil]-2-[4-(trifluorometil)fenoxi]=  
butanoicoC<sub>18</sub>H<sub>17</sub>F<sub>3</sub>O<sub>3</sub>S**perflisobutanum**

perflisobutane


1,1,1,2,3,3,3-heptafluoro-2-(trifluoromethyl)propane

perflisobutane

1,1,1,2,3,3,3-heptafluoro-2-(trifluorométhyl)propane

perflisobutano

1,1,1,2,3,3,3-heptafluoro-2-(trifluorometil)propano

C<sub>4</sub>F<sub>10</sub>**piclozotanum**


piclozotan

3-chloro-4-[4-(1',2',3',6'-tetrahydro-[2,4'-bipyridin]-1'-yl)butyl]-  
1,4-benzoxazepin-5(4*H*)-one

piclozotan

3-chloro-4-[4-(3',6'-dihydro-2,4'-bipyridinyl-1'(2'*H*)-yl)butyl]-  
1,4-benzoxazépin-5(4*H*)-one

piclozotán

3-cloro-4-[4-(3',6'-dihidro-2,4'-bipiridinil-1'(2'*H*)-il)butil]-  
1,4-benzoxazepin-5(4*H*)-onaC<sub>23</sub>H<sub>24</sub>ClN<sub>3</sub>O<sub>2</sub>

**pralatrexatum**


pralatrexate

*N*-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid

pralatrexate

acide (2*S*)-2-[[4-[(1*RS*)-1-[(2,4-diaminoptéridin-6-yl)méthyl]but-3-ynyl]benzoyl]amino]pentanedioïque

pralatrexato

ácido (2*S*)-2-[[4-[(1*RS*)-1-[(2,4-diaminopteridin-6-il)metil]but-3-inil]benzoil]amino]pentanodioico $C_{23}H_{23}N_7O_5$ **radoterminum**


radotermin

growth differentiation factor 5 (human), homodimer

radetermine

facteur 5 humain de différenciation de la croissance, homodimère produit par *E. coli*

radotermina

factor 5 humano de diferenciación del crecimiento homodímero producido por *E. coli* $C_{1184}H_{1844}N_{330}O_{350}S_{22}$ **raxibacumabum**

raxibacumab

immunoglobulin G1, anti-(anthrax protective antigen) (human monoclonal PA heavy chain), disulfide with human monoclonal PA  $\lambda$ -chain, dimer

raxibacumab

immunoglobuline G1, anti-(antigène protecteur de l'anthrax), dimère du disulfure entre la chaîne lourde et la chaîne  $\lambda$  de l'anticorps monoclonal humain PA

raxibacumab

inmunoglobulina G1, anti-(antígeno protector del antrax), dímero del disulfuro entre la cadena pesada y la cadena  $\lambda$  del anticuerpo monoclonal humano PA $C_{6320}H_{9794}N_{1702}O_{1998}S_{42}$

**rimeporidum**


rimeporide

*N*-(aminoiminomethyl)-4,5-bis(methanesulfonyl)-2-methylbenzamide

riméporide

*N*-carbamimidoyl-2-méthyl-4,5-bis(méthylsulfonyl)benzamide

rimeporida

*N*-carbamimidoil-2-metil-4,5-bis(metilsulfonyl)benzamida $C_{11}H_{15}N_3O_5S_2$ **saxagliptinum**


saxagliptin

(1*S*,3*S*,5*S*)-2-[(2*S*)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile

saxagliptine

(1*S*,3*S*,5*S*)-2-[(2*S*)-amino(3-hydroxytricyclo[3.3.1.1<sup>3,7</sup>]déc-1-yl)=acétyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile

saxagliptina

(1*S*,3*S*,5*S*)-2-[(2*S*)-amino(3-hidroxitriciclo[3.3.1.1<sup>3,7</sup>]dec-1-il)acetil]-2-azabicyclo[3.1.0]hexano-3-carbonitrilo $C_{18}H_{25}N_3O_2$ **seliciclibum**


seliciclib

(2*R*)-2-[[6-benzylamino-9-(propan-2-yl)-9*H*-purin-2-yl]amino]butan-1-ol

séliciclib

(-)-(2*R*)-2-[[6-(benzylamino)-9-(1-méthyléthyl)-9*H*-purin-2-yl]amino]=butan-1-ol

seliciclib

(-)-(2*R*)-2-[[6-(bencilamino)-9-(1-metiletíl)-9*H*-purin-2-il]amino]butan-1-ol $C_{19}H_{26}N_6O$ 

**sugammadexum**

sugammadex


cyclooctakis-(1→4)-[6-S-(2-carboxyethyl)-6-thio-α-D-glucopyranosyl]

sugammadex

cyclooctakis-(1→4)-[6-S-(2-carboxyéthyl)-6-thio-α-D-glucopyranosyl]

sugammadex

ciclooctakis-(1→4)-[6-S-(2-carboxietil)-6-tio-α-D-glucopiranosil]

 $C_{72}H_{112}O_{48}S_8$ **talabostatium**


talabostat

{(2*R*)-1-[(2*S*)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl}boronic acid

talabostat

acide [(2*R*)-1-[(2*S*)-2-amino-3-méthylbutanoyl]pyrrolidin-2-yl]=  
boronique

talabostat

ácido [(2*R*)-1-[(2*S*)-2-amino-3-metilbutanoil]pirrolidin-2-il]borónico $C_9H_{19}BN_2O_3$ **talactoferrinum alfa**

talactoferrin alfa

lactoferrin (recombinant human LF00)

talactoferrine alfa

[11-L-thréonine,29-L-arginine]lactotransferrine humaine produite par  
*Aspergillus niger* var. *awamori*

talactoferrina alfa

[11-L-treonina,29-L-arginina]lactotransferrina humana producida por  
*Aspergillus niger* var. *awamori*

C<sub>3345</sub>H<sub>5215</sub>N<sub>963</sub>O<sub>1015</sub>S<sub>37</sub> (peptide)

```

GRRRRSVQWC TVSQPEATKC FQWQRNMRRV RGPPVSCIKR
DSPIQCIQAI AENRADAVTL DGGFIYEAGL APYKLRPVAA
EYVGTERQPR THYYAVAVVK KGGSFQLNEL QGLKSCHTGL
RRTAGWNVPI GTLRPFLNWT GPPEPIEAAV ARFFSASCVP
GADKGQFPNL CRLCAGTGEN KCAFSSQEPY FSYSGAFKCL
RDGAGDVAFI RESTVFEDLS DEARDEYEL LCPDNTRKPV
DKFKDCHLAR VPSHAVVARS VNGKEDAIWN LLRQAQEKFG
KDKSPKFQLF GSPSGQKDLL FKDSAIGFSR VPPRIDSGLY
LGSGYFTAIQ NLRKSEEEVA ARRARVVWCA VGEQELRKCN
QWSGLSEGSV TCSSASTTED CIALVLKGEA DAMSLDGGYV
YTAGKCGLVP VLAENYKSQQ SSDEPDNCVD RPVEGYLAVA
VVRSDTSLT WNSVKGKKSC HTAVDRTAGW NIPMGLLFNQ
TGSCKFDEYF SQSCAPGSDP RSNLCALCIG DEQGENKCV
NSNERYGYT GAFRC LAENA GDVAFVKDVT VLQNTDGN
EAWAKDLKLA DFALLCLDGK RKPVT EARSCLAMAPNHAV
VSRMDKVERL KQVLLHQQAK FGRNGSDCPD KFCLFQSETK
NLLFNDNTEC LARLHGKTTY EKYLGPQYVA GITNLKKCST
SPLLEACEFL RK

```

\* glycosylation site  
 \* sites de glycosylation  
 \* posición de glicosilación

**talaglumetadum**


talaglumetad

(1*S*,2*S*,5*R*,6*S*)-2-[(2*S*)-2-aminopropanamido]bicyclo[3.1.0]hexane-2,6-dicarboxylic acid

talaglumétad

acide (1*S*,2*S*,5*R*,6*S*)-2-[[[(2*S*)-2-aminopropanoyl]amino]=bicyclo[3.1.0]hexane-2,6-dicarboxylique

talaglumetad

ácido (1*S*,2*S*,5*R*,6*S*)-2-[[[(2*S*)-2-aminopropanoil]amino]=biciclo[3.1.0]hexano-2,6-dicarboxílicoC<sub>11</sub>H<sub>16</sub>N<sub>2</sub>O<sub>5</sub>**tanogitrانum**

tanogitrان



*N*-[(2*R*)-2-{2-[(4-carbamimidoylanilino)methyl]-1-methyl-1*H*-benzimidazol-5-yl}-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl]glycine

tanogitrان

acide [[[(1*R*)-1-[2-[[[4-carbamimidoylphényl]amino]méthyl]-1-méthyl-1*H*-benzimidazol-5-yl]-1-méthyl-2-oxo-2-(pyrrolidin-1-yl)éthyl]=amino]acétique

tanogitrان

ácido [[[(1*R*)-1-[2-[[[4-carbamidoilfenil]amino]metil]-1-metil-1*H*-bencimidazol-5-il]-1-metil-2-oxo-2-(pirrolidin-1-il)etil]amino]=acético



**tefibazumabum**  
tefibazumab


immunoglobulin G1, anti-(*Staphylococcus aureus* protein ClfA (clumping factor A)) (human-*Mus musculus* monoclonal Aurexis heavy chain), disulfide with human-*Mus musculus* monoclonal Aurexis  $\kappa$ -chain, dimer

téfibazumab

immunoglobuline G1, anti-(protéine ClfA (facteur A d'agrégation) de *Staphylococcus aureus*) dimère du disulfure entre la chaîne lourde et la chaîne  $\kappa$  de l'anticorps monoclonal *Mus-musculus* Aurexis humanisé

tefibazumab

immunoglobulina G1, anti-(proteína ClfA (factor A de agregación) de *Staphylococcus aureus*) dímero del disulfuro entre la cadena pesada y la cadena  $\kappa$  del anticuerpo monoclonal humano *Mus-musculus* Aurexis



**temsirolimusum**  
temsirolimus

(1*R*,2*R*,4*S*)-4-[(2*R*)-2-(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3*H*-23,27-epoxypyrido[2,1-*c*][1,4]=oxazacyclohentracontin-3-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate


temsirolimus

3-hydroxy-2-(hydroxyméthyl)-2-méthylpropanoate de (1*R*,2*R*,4*S*)-4-[(2*R*)-2-[(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-9,27-dihydroxy-10,21-diméthoxy-6,8,12,14,20,26-hexaméthyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tétracosahydro-23,27-époxy-3*H*-pyrido[2,1-*c*][1,4]oxazacyclohentracontin-3-yl]propyl]-2-méthoxycyclohexyle

temsirolimus

3-hidroxi-2-(hidroximetil)-2-metilpropanoato de (1*R*,2*R*,4*S*)-4-[(2*R*)-2-[(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-9,27-dihidroxi-10,21-dimetoxi-6,8,12,14,20,26-hexametil-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahidro-23,27-epoxi-3*H*-pirido[2,1-*c*][1,4]oxazacyclohentracontin-3-il]propil]-2-metoxiciclohexilo



$C_{56}H_{87}NO_{16}$ **tetomilastum**

tetomilast


tétomilast

tetomilast

6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid

acide 6-[2-(3,4-diéthoxyphényl)thiazol-4-yl]pyridine-2-carboxylique

ácido 6-[2-(3,4-dietoxifenil)thiazol-4-il]piridina-2-carboxílico

 $C_{19}H_{18}N_2O_4S$ **thrombomodulinum alfa**

thrombomodulin alfa


thrombomoduline alfa

trombomodulina alfa

1-498-thrombomodulin (human clone TMP26/TMJ1 protein moiety reduced)

[473-valine]précurseur de la thrombomoduline humaine-(19-516)-peptide (protéine soluble)

[473-valina]precursor de la trombomodulina humana-(19-516)-péptido (proteína soluble)



```

                                AP AEPQPGGSQC VEHDCFALYP
GPATFL*NASQ ICDGLRGHLM TVRSSVAADV ISLLLNGDGG
VGRRLWIGL QLP*PGCGDPK RLGPLRGFQW VTGD*NNTSYS
RWARLDLNGA PLC*GPLCVAV SAAEATVPSE PIWEEQQCEV
KADGFL*CEFH FPAT*CRPLAV EPGAAAAVS ITYGTPFAAR
GADFQALPVG SSAAVAPLGL QLMCTAPPGA VQGHWAREAP
GAWD*CSVENG GCEHACNAIP GAPRCQCPAG AALQADGRSC
TASATQSCND LCEHFCVPNP DQPG*SYSCMC ETGYRLAADQ
HRCEDVDDCI LEPS*PCPQRC VNTQGGFECH CYPNYDLVDG
ECVEPVDP*CF RANCEYQCQP LN*QTSYLCVC AEGFAPIPHE
PHRCQMFC*NQ TACPADC*DPN TQASCECPEG YILDDGFICT
DIDECENG*GF CSGVCHNLPG TFECIC*GPDS ALVRHIGTDC
DSGKVDGGDS GS*GEPPP*SP*T PG*STLT*PPAV GLVHSG

```

\* glycosylation sites

\* sites de glycosylation

\* posiciones de glicosilación

**AMENDMENTS TO PREVIOUS LISTS  
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES  
MODIFICACIONES A LAS LISTAS ANTERIORES**

**Proposed International Non Proprietary Names (Prop. INN): List 92**  
**Dénominations communes internationales proposées (DCI Prop.): Liste 92**  
**Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 92**  
**(WHO Drug Information, Vol. 18, No. 4, 2004)**

|        |   |   |
|--------|---|---|
| p. 351 | <i>suprimáse</i><br><b>temserolimusum</b><br>temserolimus | <i>insértese</i><br><b>temsirolimusum</b><br>temsirolimus |
|--------|---|---|

p. 354    **thrombomodulinum alfa**  
 thrombomodulin alfa  
 thrombomoduline alfa  
 trombomodulina alfa

*replace the graphic formula by the following:*  
*remplacer la formule développée par:*  
*sustitúyase la fórmula desarrollada por:*

```

                                AP AEPQPGGSQC VEHDCFALYP
GPATFLNASQ ICDGLRGHLM TVRSSVAADV ISLLLNGDGG
VGRRLWIGL QLPPGCGDPK RLGPLRGFQW VTGDNNTSYS
RWARLDLNGA PLCGPLCVAV SAAEATVPSE PIWEEQQCEV
KADGFLCEFH FPATCRPLAV EPGAAAAVS ITYGTPFAAR
GADFQALPVG SSAAVAPLGL QLMCTAPPGA VQGHWAREAP
GAWDCSVENG GCEHACNAIP GAPRCQCPAG AALQADGRSC
TASATQSCND LCEHFCVPNP DQPGSYSCMC ETGYRLAADQ
HRCEDVDDCI LEPSPCPQRC VNTQGGFECH CYPNYDLVDG
ECVEPVDPCF RANCEYQCP LNQTSYLCVC AEGFAPIPHE
PHRCQMFCNQ TACPADC DPN TQASCECPEG YILDDGFICT
DIDECENGGF CSGVCHNLPG TFEICGPD S ALVRHIGTDC
DSGKVDG GDS GSGEPPPSPT PGSTLTTPPAV GLVHSG
  
```

\* glycosylation sites  
 \* sites de glycosylation  
 \* posiciones de glicosilación

**Recommended International Nonproprietary Names (Rec. INN): List 16**  
**Dénominations communes internationales recommandées (DCI Rec.): Liste 16**  
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 16**  
**(WHO Drug Information, Vol. 30, No. 10, 1976)**

|      |  |  |
|------|--|--|
| p. 6 | <b>nosiheptidum</b><br>nosiheptide<br>nosiheptide<br>nosiheptida | <i>replace the molecular formula by the following:</i><br><i>remplacer la formule brute par:</i><br><i>sustitúyase la fórmula empírica por:</i><br>$C_{51}H_{43}N_{13}O_{12}S_6$ |
|------|--|--|

**Recommended International Nonproprietary Names (Rec. INN): List 34**  
**Dénominations communes internationales recommandées (DCI Rec.): Liste 34**  
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 34**  
**(WHO Drug Information, Vol. 8, No. 3, 1994)**

|      |                               |                              |
|------|-------------------------------|------------------------------|
| p. 5 | <i>suprimase</i><br>bosentano | <i>insértese</i><br>bosentán |
|------|-------------------------------|------------------------------|

**Recommended International Nonproprietary Names (Rec. INN): List 52**  
**Dénominations communes internationales recommandées (DCI Rec.): Liste 52**  
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 52**  
**(WHO Drug Information, Vol. 18, No. 3, 2004)**

p. 252 *suprimáse* *insértese*  
 esoxybutynina esoxibutinina

p. 258 *suprimáse* *insértese*  
 ramelteón ramelteón

**Recommended International Nonproprietary Names (Rec. INN): List 53**  
**Dénominations communes internationales recommandées (DCI Rec.): Liste 53**  
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 53**  
**(WHO Drug Information, Vol. 19, No. 1, 2005)**

p. 74 **dasantafilem**  
 dasantafile  
*replace the chemical name by the following:*  
 7-(3-bromo-4-methoxyphenylmethyl)-1-ethyl-8-[[[(1*R*,2*R*)-2-hydroxycyclopentyl]=  
 amino]-3-(2-hydroxyethyl)-3,7-dihydro-1*H*-purine-2,6-dione

p. 75 **deluceminum**  
 delucemine  
 delucémine  
 delucemina  
*replace the molecular formula by the following:*  
*remplacer la formule brute par:*  
*sustitúyase la fórmula empírica por:*  
 $C_{16}H_{17}F_2N$

p. 84 **maravirocum**  
 maraviroc  
*replace the chemical name by the following:*  
 4,4-difluoro-*N*-[(1*S*)-3-[(1*R*,3*S*,5*S*)-3-[3-methyl-5-(propan-2-yl)-4*H*-1,2,4-triazol-  
 4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexanecarboxamide

**Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales**

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.